| Metoclopramide response in patients with early diffuse systemic sclerosis. Effects on esophageal motility abnormalities. | |
| | |
MedLine Citation:
|
PMID: 16173247 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To assess the metoclopramide response in patients with early diffuse systemic sclerosis (dSSc) and the acute effects of intravenous (IV) metoclopramide on the lower esophageal sphincter (LES). METHODS: Twenty-one patients with early dSSc (mean age 41.4 +/- 9.8 yrs., mean disease duration 2.47 +/- 0.75 yrs.) were prospectively evaluated. Six patients with late dSSc (mean age 52.6 +/- 9.1 yrs., mean disease duration 9.5 +/- 2.5 yrs.) were used as control group. All underwent solid-state esophageal manometry at rest and 15 minutes later received 10 mg of metoclopramide in an intravenous single bolus. RESULTS: We found that the mean LES pressures measured by the station pull-through technique significantly increased in both early and late dSSc patients after metoclopramide administration (p < 0.05). While early dSSc patients did improve the mean residual pressures (p < 0.05), late dSSc patients did not (p > 0.05). In the esophageal body (EB), the mean contractions amplitude at 18, 13, 8, and 3 cm above the LES was < 20 mm Hg for both groups. However, peristaltic contraction velocitiy was significantly higher in early dSSc patients (< 0.05) than in that with late dSSc (p > 0.05). Our study did not show any major differences when comparing both groups. No side effects were seen. CONCLUSIONS: The results of our study show that metoclopramide may improve LES pressures in patients with early and late dSS. Metoclopramide improve the mean residual pressure in patients with early dSSc, but not in late dSSc patients. Although esophageal contractions amplitude were significantly improved, they did not achieve a pressure > 20 mm Hg. Because metoclopramide can be used orally, it may mitigate both dysphagia and heartburn. |
| | |
Authors:
|
U Mercado; R Arroyo de Anda; L Avendaño; R Araiza-Casillas; M Avendaño-Reyes |
Related Documents
:
|
2920457 - The location of the upper oesophageal sphincter and its behaviour during bolus propagat... 7284737 - Lord's procedure for haemorrhoids: a prospective anal pressure study. 8064197 - Anal pressure vectography is of no apparent benefit for sphincter evaluation. 8519877 - The pressure area: a variable for the assessment of anal sphincter function. 15069567 - Effect of bimatoprost on ocular circulation in patients with open-angle glaucoma or ocu... 19935637 - Ventilatory management of one-lung ventilation. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Clinical and experimental rheumatology Volume: 23 ISSN: 0392-856X ISO Abbreviation: Clin. Exp. Rheumatol. Publication Date: 2005 Sep-Oct |
Date Detail:
|
Created Date: 2005-09-21 Completed Date: 2005-12-21 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8308521 Medline TA: Clin Exp Rheumatol Country: Italy |
Other Details:
|
Languages: eng Pagination: 685-8 Citation Subset: IM |
Affiliation:
|
Hospital General Mexicali, ISESALUD and Universidad Autonoma de Baja California, Mexicali, Mexico. ulisesmercado@uabc.mx |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Esophageal Motility Disorders / drug therapy*, etiology Esophageal Sphincter, Lower / drug effects* Female Gastrointestinal Agents / administration & dosage* Humans Infusions, Intravenous Male Metoclopramide / administration & dosage* Middle Aged Scleroderma, Systemic / complications* Time Factors Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Gastrointestinal Agents; 364-62-5/Metoclopramide |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Inclusion criteria as widely used for rheumatoid arthritis clinical trials: patient eligibility in a...
Next Document: Is there a role of free oxygen radicals in primary male osteoporosis?